{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Determine Progression Free Survival at 1 year defined as the percentage of patients who are alive at 1 year after beginning of their concurrent re-irradiation and chemotherapy without loco-regional progression of their disease as measured by CT scan or MRI.","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Progression-free Survival (PFS) at 1 Year (Phase II)","type":"PRIMARY","unitOfMeasure":"Participants"}